Eli Lilly (LLY) Shares Outstanding (Weighted Average) (2009 - 2026)

Eli Lilly has reported Shares Outstanding (Weighted Average) for 18 years, with the latest figure at $894.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) changed 0.47% year-over-year to $894.5 million; the trailing twelve-month figure through Mar 2026 stood at $894.5 million (changed 0.47% YoY), and the FY2025 full-year result was $897.3 million, changed 0.37% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $894.5 million, roughly flat from $897.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $903.7 million in Q1 2022, with the low at $894.5 million in Q1 2026.
• Historically, Shares Outstanding (Weighted Average) has averaged $900.0 million across 5 years, with a median of $900.6 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) dropped 0.68% — and 2024, when it climbed 0.13%.
• Eli Lilly's Shares Outstanding (Weighted Average) stood at $901.7 million in 2022, then fell by 0.17% to $900.2 million in 2023, then increased by 0.04% to $900.6 million in 2024, then retreated by 0.37% to $897.3 million in 2025, then dropped by 0.31% to $894.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $894.5 million (Q1 2026), $897.3 million (Q4 2025), and $897.8 million (Q3 2025), per Business Quant data.